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Aim/background: We  sought to determine the tolerance level and complication rates of the
vaginal vault to combined high-dose-rate intra-cavitary brachytherapy with concomitant
chemo-radiotherapy.
Patients and methods: A retrospective review of medical records of all the patients who
received deﬁnitive chemo-radiotherapy for cervical cancer between 1998 and 2002 was
undertaken. The records were reviewed for doses and for radiation-associated early and
late  sequelae of the vagina, rectum and bladder. Cumulative biological effective dose was
calculated for two reference vaginal surface points.
Results: Fifty patients were included. Average age at diagnosis was 54 years. Median follow-up
was 59 months. There were no recorded instances of acute grade IV toxicity. Maximal high-
dose-rate vaginal surface dose (upper central point) was 103 Gy, and maximal brachytherapy
lateral surface dose was 70 Gy. Maximal cumulative biological effective dose for the lateral
surface reference point was 465.5 Gy3, and the maximal cumulative biological effective dose
for  the superior reference point was 878.6 Gy3. There were no cases of vaginal necrosis or
ﬁstulas, and no cases of grade IV late vaginal, rectal or bladder toxicity. No correlation was
found between the maximal vaginal surface dose and vaginal, rectal or bladder toxicity.
Conclusions: The maximal surface HDR brachytherapy dose of 103 Gy and the maximal cBEDof  878.6 Gy3 were not associated with ﬁstula or necrosis or other grade 3–4 vaginal complica-
tions. Concomitant chemo-radiotherapy, including pelvic radiotherapy and high-dose-rateintracavitary brachythera
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the radius of the ovoid. For each patient, the total vaginal dose
F
Ereports of practical oncology an
.  Background
he treatment of locally advanced uterine-cervix cancer
ncludes concomitant chemo-radiotherapy and intracavitary
rachytherapy as deﬁnitive treatment. Radiotherapy doses
hould be optimized to achieve maximal tumor control but
reat caution needs to be taken to avoid life-threatening or
isabling early and late complications. Brachytherapy allows
or creating dose escalation which is possible since the toler-
nce dose of the proximal vagina (vault), uterine-cervix and
terus is high.1,2
Numerous factors need to be taken into account when
lanning the treatment, apart from the patient’s habi-
us and tumor conﬁguration. Procedural factors associated
ith source placement are often important factors affect-
ng outcome. Vaginal shortening can occur during treatment;
herefore, doses to more  distal areas of the vagina, which
re considered to be less tolerant than the proximal vagina,
ay increase during treatment.3 These factors may prevent
he use of optimal brachytherapy, smaller applicators and
ini ovoids, which might cause the vaginal vault mucosa
olerance dose to become a dose-limiting factor.1 Moreover,
he shift from intracavitary low-dose rate (LDR) brachyther-
py to intracavitary high-dose-rate (HDR) brachytherapy has
ed to some uncertainty. As opposed to LDR brachytherapy,
here is no standardized way to deliver HDR brachytherapy,
nd treatments vary considerably between institutions. Dwell
ime patterns change from patient to patient, to allow opti-
ization of dose distributions according to tumor geometry.4
ractionation of HDR with four to six fractions can be applied
o achieve nominal complication rates similar to LDR. How-
ver, HDR complication rates are likely to be susceptible to
inor changes of dose and biological parameters, due to the
mpliﬁed biological effects.1
The development of complications is multifactorial and
ncludes medical comorbidities, total dose of radiation, dose
er fraction, number of fractions, dose rate, radiation ﬁeld,
adiation technique, and whether surgery was performed
rior to radiotherapy.1 There are only a few reports of vaginal
ecrosis secondary to radiotherapy, most reported in patients
reated with adjuvant concomitant chemoradiotherapy.5–7
ublications often lack important components of treatment
lanning, doses, vaginal surface dose, complications, treat-
ent failure, and other vital clinical data.4 Since the advent
f 3D planning, the rectum and bladder have been given
ew restrictions according to volume, while the vaginal vault
olerance dose is still in the dark. Moreover, deﬁnitive treat-
ent for cervical cancer includes concomitant chemotherapy
nd external beam radiotherapy (EBRT) together with HDR
rachytherapy, and all should be taken into account when cal-
ulating the exposed doses of the mucosa (vagina, rectum, and
ladder). The addition of chemotherapy is expected to narrow
ig. 1 – Equation used for calculation of cumulative biological eff
BRT: external beam radiotherapy. The / ratio used was 3 for liotherapy 1 9 ( 2 0 1 4 ) 56–61 57
the therapeutic window when combined treatment is applied.
More studies are needed to evaluate the outcome of deﬁni-
tive treatment for uterine-cervix cancer, encompassing both
detailed dosimetric and clinical aspects of treatment, to serve
as a guide for non-compromising treatment of this potentially
curable disease.1
Severe complications after radiotherapy for cervical can-
cer may occur decades after treatment completion.6 There is
a paucity of information regarding late toxicity after chemo-
radiation for locally advanced cervical cancer, while total
vaginal necrosis after treatment is rarely reported.8 The pur-
pose of the current study was to determine the tolerance levels
and late complication rates of the vaginal vault to combined
concomitant chemotherapy with external pelvic irradiation
and intracavitary HDR brachytherapy, mostly late occurring
vaginal necrosis. Complications of adjacent organs were also
recorded, as well as survival, recurrences and other clinical
data.
2.  Patients  and  methods
A single center, retrospective study of the medical records of
all consecutive patients with carcinoma of the uterine cervix
treated between May 1998 and May 2002 with concomitant
external beam radiotherapy, weekly chemotherapy, and intra-
cavitary HDR brachytherapy was conducted. All the patients
were treated with curative intent.
The medical records of 50 consecutive locally advanced
patients were reviewed for radiotherapy doses and radiation-
associated late sequelae of the proximal vagina (vault) with an
emphasis on late-occurring vaginal necrosis. Complications of
the rectum and bladder were also recorded. Vaginal patency
was graded according to vaginal examination recorded in
the medical ﬁles. The recorded examinations were reviewed
and scored by an onco-gynecologist into four levels (level
0 – no toxicity; 1 – mild; 2 – moderately obliterated and
shortened vagina; level 3 – complete vaginal obliteration).
Vaginal, rectal and bladder toxicity were graded according to
the Common Terminology Criteria for Adverse Events (CTCAE)
Version 4.0 (September 2009). Data collected included demo-
graphics, follow-up, time and site of recurrence, mortality,
sexual activity, and the presence and site of other malignan-
cies.
The HDR planning process was based on 2D planning. In
order to evaluate the doses received by the vaginal mucosa,
two sets of points were deﬁned for each ovoid: 5 points on
the uppermost and 5 points on the lateral surface of the ovoid
opposite the ﬁve active dwell positions at a distance equal tofor the whole HDR treatment was calculated on the surface of
the ovoids at the lateral and the upper central point according
to the method in our previous publication by Nevelsky et al.9
ective dose (cBED). HDR: high-dose-rate brachytherapy;
ate responding tissue.
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The cumulative biological effective dose (cBED) was calcu-
lated for two reference vaginal surface points. The equation
used for calculation for cBED is presented in Fig. 1. The /
ratio used was 3 for late responding tissues. The total physical
dose was calculated as the sum of the physical external dose
and the physical maximal brachytherapy dose (as calculated
according to the above cited method).
3.  Statistical  analysis
The statistical software package used was SPSS-18. Descrip-
tive statistics are presented in terms of mean and median. As
the maximal total dose and the maximal brachytherapy dose
were not normally distributed by the Kolmogorov–Smirnov Z
test, the Mann–Whitney U test and Kruskal–Wallis test were
used for differences between groups. A value of P < 0.05 was
considered as signiﬁcant.
4.  Results
Patients. Average age at diagnosis of the 50 consecutive
patients who comprised the study population was 54.3 ± 12.9
years (range, 30–87 years). Median follow-up was 59 months
(range, 4–132 months). Patient characteristics are summa-
rized in Table 1. In two patients, the initial planned treatment
was surgery but, due to the extent of the disease found dur-
ing the procedure, it was decided to abort the operation and
the patients were referred for deﬁnitive chemo-radiotherapy.
One patient underwent surgery due to a pelvic abscess,
and the diagnosis of cervical cancer was established during
this procedure; this patient underwent unilateral salpingo-
oophorectomy due to the proximity to the abscess and then
was referred for deﬁnitive chemo-radiotherapy. Seven patients
were lost to follow-up for evaluation of long-term toxicity;
however, data of overall survival were available for all the
patients and was based on the results of the population cen-
sus as recorded in the population registry of the Ministry of
the Interior.
Table 1 – Patients’ characteristics (n = 50).
n of patients
Histology
Squamous cell carcinoma 39
Adenocarcinoma 2
Other 5
FIGO stage
1B1 1
1B2 bulky 13
2B 29
3B 6
Unknown 1
Grade
1 3
2 16
3 19
Unknown 12diotherapy 1 9 ( 2 0 1 4 ) 56–61
Treatment. Forty-eight patients received concomi-
tant chemo-radiotherapy (pelvic EBRT) followed by HDR
brachytherapy. One patient received EBRT and HDR
brachytherapy without chemotherapy because of Crohn’s dis-
ease. One patient received concomitant chemo-radiotherapy
(pelvic EBRT) at a different institution; the chemother-
apy regimen given was not documented in the medical
record. For all patients, EBRT was performed prior to HDR
brachytherapy. Cisplatin at a dose of 40 mg/m2 was used con-
comitantly with pelvic irradiation in all except two patients
in whom carboplatin was used (area under the curve of
2) due to renal insufﬁciency. Not all the patients received
the planned chemotherapy cycles: acute gastrointestinal
toxicity (diarrhea) was the main indication to discontinue
chemotherapy.
EBRT. Patients were planned to be treated with external
radiotherapy to the pelvis at a dose of 45–50.4 Gy (25–28 frac-
tions, 1.8 Gy per fraction, 5 fractions per week) using 6 MV
or 18 MV beams from a Varian Clinac 1800 linear accelera-
tor (Varian Medical Systems, Inc., Palo Alto CA), according to
our department’s protocol. The actual doses were 39.6–50.4 Gy
(average, 45–47 Gy). Four patients received 46 Gy, 2 Gy per frac-
tion. Depending on the patient’s body habitus, either two
opposing (anterior–posterior) ﬁelds (true for most patients) or
the 4-ﬁeld box technique (for larger body habitus) were used.
Twenty-one (42%) patients had gross parametrium involve-
ment and an EBRT boost was added. Median boost dose was
10 Gy given as 2 Gy per fraction, 5 fractions per week (range,
5.4–10 Gy). The boost was given with a central block in the
vagina and uterine-cervix area.
HDR brachytherapy. HDR brachytherapy was performed
using the MicroSelectron system (Nucletron, an Elekta com-
pany (Elekta AB, Stockholm, Sweden) using Ir192 source. Prior
to the ﬁrst HDR brachytherapy fraction, patients underwent
intrauterine stent insertion. Brachytherapy was performed
with gauze packing. Intrauterine applications were performed
in the lithotomy position. Nucletron (Elekta) “Fletcher-Suit
like” tandem and ovoid applicators were used, with tandem
curvatures of 15◦, 30◦, or 45◦, and ovoid cap diameters of 16,
20, or 25 mm.  The HDR fractionation scheme was planned for
ﬁve fractions of 5–5.5 Gy each (depending on clinical evalu-
ation of the tumor size). The Nucletron (Elekta) PLATO BPS
v.13.7 treatment planning system was used. Treatment doses
were prescribed at point “A”. Doses according to the Inter-
national Commission on Radiation Units and Measurements
(ICRU) rectal and bladder reference points, and point “B” doses
(ICRU Report 38) were recorded for each treatment.10 As a stan-
dard, ﬁve active dwell positions separated by 5 mm steps were
used in each ovoid to reproduce a traditional 2 cm LDR Cs137
source. Manual optimization of dwell times was performed
in both the “ovoids” and the “tandem” to minimize rectal and
bladder doses while retaining the traditional “pearshape” dose
distribution. Brachytherapy sessions were conducted once a
week. Two patients did not complete ﬁve HDR brachyther-
apy sessions (3 and 4 sessions out of 5 planned sessions). In
the patient who received three HDR sessions, the intrauter-
ine stent was displaced after the third session; she was given
another single LDR fraction of 18 Gy to point “A”. One patient
received four sessions of 6.25 Gy and another patient received
ﬁve sessions of 5.9 Gy.
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Fig. 2 – Brachytherapy doses for the lateral ovoid point and
the upper central point (cGy).
Fig. 3 – Cumulative biological effective dose (cBED) for all
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Table 2 – Late rectal and bladder complications.
CTCAE gradea Urinary n of patients
2 Macroscopic hematuria 3
2 Cystitisa 3
2 Urinary incontinence 5
CTCAE
gradea
Gastrointestinal n of patients
1–2 Diarrhea 9
2
One patient
had grade 3
proctitis
Proctitisb 4
3 Incomplete bowel obstruction 1
Notes: No correlation was found to total physical dose of EBRT and
HDR or maximal HDR brachytherapy dose (P = NS).
a Common Terminology Criteria for Adverse Events (CTCAE) Ver-
there were no cases of vaginal ulceration, ﬁstula or necrosis atatients (Gy3).
Fig. 2 summarizes the brachytherapy doses for the lat-
ral ovoid point and the maximal brachytherapy point (upper
entral point) for each patient. The maximal HDR vaginal
urface dose (upper central point) was 103 Gy. The maximal
rachytherapy lateral surface dose was 70 Gy.
Cumulative biological effective dose. The cBED for all
atients is presented in Fig. 3. The cBED calculated using the
ateral surface reference point was a median of 269 Gy3 (range,
68.5–465.5 Gy3). The cBED calculated using the upper central
eference point was 368.5 Gy3 (range, 226–878.6 Gy3).
Vaginal, rectal and bladder toxicity. Seven patients were
ost to follow-up for evaluation of long-term toxicity. There
ere no ﬁstulas (recto-vaginal or cysto-vaginal) or CTCAE
rade IV late vaginal, rectal or bladder toxicity. Rectal and blad-
er toxicity are summarized in Table 2. There were no cases
f necrosis of the distal vagina or vaginal vault. No relation-
hip was found between the total physical dose of EBRT plus
DR/or maximal HDR brachytherapy dose and the severity of
aginal, rectal or bladder complications (P = NS).
Detailed vaginal examinations recorded in the medical
les, which enabled the assessment of late vaginal patencysion 4.0.
b Proven by endoscopy.
(≥12 months), were available for 25 patients: 7 (28%) patients
had no obliteration, 7 (28%) patients had mild shortened
vagina, 7 (28%) patients had moderately obliterated and short-
ened vagina, and 4 (16%) patients suffered from complete
vaginal obliteration.
Data of intercourse were available for 12 patients during
long-term follow-up (≥12 months), and four of these patients
indicated being sexually active. Eight patients indicated that
they were not sexually active, four due to partner issues (part-
ner’s medical condition or no partner). One patient indicated
that she suffered from dyspareunia.
Recurrence, second malignancy and overall survival. Thir-
teen patients had recurrent disease, nine of whom had distant
recurrences. Two patients were staged at diagnosis as FIGO 1B2
bulky disease, two were FIGO 2B, and ﬁve patients were FIGO
3B. Nine of 43 (20%) patients had a second primary malignancy.
In two patients, the secondary malignancy was within the irra-
diation ﬁeld: one patient had a bladder carcinoma in situ and
one patient was diagnosed with ovarian cancer one year after
completion of treatment. Overall survival rate was 25% for 50
patients.
5.  Discussion
In the current study, the tolerance dose of the vaginal vault and
late complications were assessed based on clinical data of 50
patients. Median follow-up was 59 months, as a tertiary insti-
tution some patients after a period of time (usually 5 years)
are referred back to their community physician. The maximal
surface HDR brachytherapy dose of 103 Gy and the maximal
cBED of 878.6 Gy3 were not associated with ﬁstula or necro-
sis or other grade 3–4 vaginal complications. These ﬁndings
are similar to those reported by Toita et al.11 In their study,a median follow-up of 48 months with a vaginal cBED ranging
from 185.5 to 618 Gy3 (median, 324 Gy3). The cBED in that study
was calculated according to the dose prescribed to point “A”,
nd ra
r60  reports of practical oncology a
which is probably lower than the calculated vaginal surface
dose which was used to calculate cBED in the current study.9
A retrospective analysis of 222 consecutive patients receiv-
ing radical treatment for invasive cervical cancer reported a
higher rate of recto-vaginal cases of ﬁstula, the investigators
found a strong association between the risk of developing a
ﬁstula and the BED at rectal reference point.12
The sum of physical doses of EBRT (without the boost) and
maximal HDR dose in the current study was 148 Gy. This sum
of physical doses was conducted for a “historical control” and
should not be used in practice.1,2 However, the value is similar
to that reported by Au and Grigsby,1 238 Gy for LDR brachyther-
apy.
No correlation was found between the values of the max-
imal HDR surface doses calculated and vaginal, rectal or
urinary complications, indicating that these complications
might follow a stochastic model.
Radiobiologically-wise, HDR-brachytherapy is expected
to result in more  normal tissue toxicity than LDR-
brachytherapy.13 Yet our study had similar complication rates
to those reported by Au and Grigsby1 for LDR brachytherapy.
In that study as well, there were no grade 4 complications. In
the current study, all patients were treated by using tandem
and ovoid applicators. More  studies are needed to evaluate
the doses when a ring applicator is used, as it may result in
a slightly narrower distribution, leading to a higher vaginal
dose and potentially higher toxicity.14
The primary endpoint of our study was the evaluation of
late vaginal toxicity (primary – vaginal necrosis) according to
the HDR intracavitary brachytherapy doses that were given.
The cBED was calculated based on both external beam dose
and HDR-brachytherapy dose. When using the lateral surface
reference point, the cBED was a median of 269 Gy3 (range,
168.5–465.5 Gy3) and the cBED calculated using the upper
central reference point was 368.5 Gy3 (range, 226–878.6 Gy3)
without vaginal cuff necrosis and/or ﬁstula, at a median
follow-up of 59 months. Our study indicates that the vagi-
nal vault tolerance to HDR intracavitary brachytherapy is high,
similar to the reports of Au and Grigsby1 for LDR brachyther-
apy. It seems that the tolerance of the vaginal cuff is greater
than cBED of 368.5 Gy3. However, the study has a small patient
population and conclusions should be drawn with caution.
We also reported the rates of vaginal obliteration; however,
we do not consider this as an endpoint for estimating vagi-
nal vault tolerance. The development of vaginal obliteration
also depends on other cofactors, such as vaginal involvement,
length of the treated vagina, vaginal washings after treatment,
regular dilation, sexual activity, etc. Owing to the retrospective
nature of this study, this information was only partially avail-
able. In our practice, all patients are routinely instructed to use
vaginal dilators. Vaginal obliteration in this young patient pop-
ulation is a disabling side effect, and efforts should be made
to avoid this complication.
Combinations of dose-speciﬁcation methods, insertion
techniques and normal tissue dose relationships from differ-
ent clinical systems can be dangerous and should be avoided.
There are many  differences between HDR treatment plans
and it is very challenging (or impossible) to evaluate a true
biological–clinical effect. Thus, there is a need for a spec-
trum of maximal surface doses that are safe without causingdiotherapy 1 9 ( 2 0 1 4 ) 56–61
vaginal-vault necrosis and acceptable long-term complication
rates. Hopefully, data of long-term follow-up of 3D image-
guided brachytherapy will be available in the near future to
aid in the determination of appropriate tolerance levels of the
vaginal mucosa.
Although our study is a retrospective report of 2D tech-
nique, it should be emphasized that 2D is still employed
in some countries in which this disease is prevalent. Since
our data provide spatial information of maximal dose, it
is of utmost importance, as this information is not pro-
vided by the DVH. According to our study, the maximal
surface HDR brachytherapy dose of 103 Gy and the maximal
cBED of 878.6 Gy3 were not associated with ﬁstula or necro-
sis or other grade 3–4 vaginal complications. Concomitant
chemo-radiotherapy, including pelvic radiotherapy and high-
dose-rate intracavitary brachytherapy, is relatively safe for
cervical cancer patients.
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